(Q37849628)

24 August 2017

1 reference

title

In search of CML stem cells' deadly weakness (English)

1 reference

24 August 2017

Tessa L Holyoake

3

0 references

author name string

Francesca Pellicano

series ordinal

1

1 reference

PubMed ID

21373837

24 August 2017

Amy Sinclair

series ordinal

2

1 reference

24 August 2017

1 June 2011

1 reference

Current hematologic malignancy reports

24 August 2017

1 reference

24 August 2017

6

1 reference

24 August 2017

2

1 reference

24 August 2017

82-87

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-011-0085-y

24 August 2017

0 references

cites work

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

PML targeting eradicates quiescent leukaemia-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

The interleukin 1 receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Jak2 is essential for signaling through a variety of cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Jak2 is involved in c-Myc induction by Bcr-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Janus kinase 2: a critical target in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Multiple pathways regulated by the tumor suppressor PP2A in transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

MicroRNAs: regulators of gene expression and cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

MicroRNAs modulate hematopoietic lineage differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Do we have to kill the last CML cell?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0085-Y

Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells

21 January 2018

1 reference

12 December 2020

Targeted therapy in haematological malignancies

1 reference

12 December 2020

Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1

1 reference

12 December 2020

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

12 December 2020

Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1

1 reference

12 December 2020

Stage-specific expression of polycomb group genes in human bone marrow cells

1 reference

12 December 2020

10.1007/S11899-011-0085-Y

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21373837